Dainippon Sumitomo on the Ras as it locks in cancer candidates from Kobe partners
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) is continuing its push to build up in-house R&D in the oncology area through a new agreement with two partners in Japan for small molecule Ras inhibitors.